Memantin Stada (Memantine)

Memantine works by blocking the NMDA (N‑methyl‑D‑aspartate) receptor in the brain. This non‑competitive antagonism reduces excessive calcium influx caused by prolonged glutamate activity, limiting excitotoxic neuronal damage while preserving normal synaptic signaling.

The dosing regimen for Memantin Stada is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber will typically start with a low dose and titrate upward as needed.

Safety data for memantine during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To order Memantin Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

The primary alternative class for Alzheimer’s disease is cholinesterase inhibitors such as donepezil. While cholinesterase inhibitors increase acetylcholine levels, memantine modulates glutamate‑mediated excitotoxicity. Memantine is typically used in moderate to severe disease or in combination with a cholinesterase inhibitor to provide complementary mechanisms of action.

Memantin Stada tablets should be stored at room temperature, below 25 °C, in the original blister pack. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Memantin Stada is taken orally. The tablet should be swallowed whole with water, with or without food, as directed by the prescriber. Patients should follow the titration schedule provided by their healthcare professional.

Serious risks include severe allergic reactions (rash, swelling, breathing difficulty), Stevens‑Johnson syndrome or toxic epidermal necrolysis, seizures, and new or worsening hallucinations or psychotic symptoms. Any of these events require immediate medical attention.

Memantin Stada should be avoided in patients with known hypersensitivity to memantine or any excipients, in those with severe renal impairment without dose adjustment, and in individuals taking other NMDA antagonists where additive neurotoxicity could occur. Clinicians should evaluate each patient’s medical history before initiating therapy.